Posted by Michael Wonder on 04 Oct 2016
NICE published draft guidance on a new use for Keytruda
4 October 2016 - NICE has published draft guidance on the use of Keytruda (pembrolizumab) by patients with non-small-cell lung cancer.
Pembrolizumab is not recommended, within its marketing authorisation, for treating locally advanced or metastatic non-small-cell lung cancer in adults whose tumours express PD-L1 and who have had at least one prior chemotherapy regimen (and targeted treatment if they have an epidermal growth factor receptor [EGFR]- or anaplastic lymphoma kinase [ALK]-positive tumour).
